Stem Cell Transplantation for Hematological Malignancies

Stopped early · Phase 2/Phase 3

Conditions studied: Leukemia, Lymphocytic, Acute, AML, MDS

In brief

This protocol using busulfan, cyclophosphamide and melphalan has been designed as conditioning therapy for patients receiving stem cell transplantation for acute leukemia or myelodysplastic syndrome (MDS). The hypothesis is that this new regimen will be well tolerated and will cure the patient.

Key facts

Study ID
NCT00176839
Run by
Masonic Cancer Center, University of Minnesota
People needed
11
Starts
2000-06-07
Expected to finish
2012-02-01
Last updated by the study team
2017-12-05

Who can join

Age: any, up to 35. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.